Management of ASCVD in Patients with CKD: Present, Past, and Future

Program Description

In the past several years, scientific advances have revealed a promising role for anti-inflammatory agents in treating patients with CKD who are at high risk for developing ASCVD. As new therapeutic targets are identified, clinical studies are designed to assess novel anti-inflammatory therapies to mitigate residual inflammation in ASCVD in CKD. In this educational program, cardiologist Dr. Paul Ridker and nephrologist Dr. Katherine Tuttle discuss lessons learned from previous clinical trials and take a forward look to the design of ongoing trials and their emerging results. They also discuss how multidisciplinary management may evolve with new therapies that could become available to patients in the coming years.

Target Audience

The educational design of this activity addresses the needs of cardiologists and a secondary audience of nephrologists, as well as to other healthcare providers (HCPs) involved in the care of patients at risk for developing atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). 

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Describe the clinical profiles of novel targeted anti-inflammatory therapies in ASCVD, highlighting ongoing clinical trial results

2. Implement a multidisciplinary approach to managing ASCVD risks in patients with CKD 

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Relevant Financial Relationships

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Paul M. Ridker, MD, MPH: Contracted Research: Amarin Corporation plc, Esperion Therapeutics, Inc., Kowa Pharmaceuticals America, Inc., National Heart, Lung, and Blood Institute, Novartis AG, Novo Nordisk Inc., Pfizer Inc.; Consulting Fees: Agepha Pharma FZ LLC, Ardelyx Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Cardiol Therapeutics Inc., CiVi Biopharma, CSL Behring, Cytokinetics, Incorporated, Eli Lilly & Company, Flame Pharmaceuticals Pvt Ltd., GSK plc, Health Outlook, Horizon Therapeutics, Janssen Pharmaceuticals, Montai Therapeutics, NewAmsterdam Pharma Corporation, Novartis AG, Novo Nordisk Inc., RTI International, SOCAR Research SA, Zomagen Biosciences Ltd; Stock Options: Angiowave,  Bitteroot Bio; Advisory Boards: Baim Institute for Clinical Research, Leducq Foundation, Paris FR, Peter Munk 

Katherine R. Tuttle, MD, FASN, FACP, FNKF: Consulting Fees: AstraZeneca plc (to institution), Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk Inc., ProKidney Corp., Pfizer Inc.; Contracted Research: Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk Inc. (to institution), Travere Therapeutics

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact Integritas Communications at info@exchangecme.com.